Non-surgical palliative treatment of patients with malignant biliary obstruction--the place of endoscopic and percutaneous drainage

Comparison of Biliary Drainage Techniques for Malignant Biliary Obstruction: A Systematic Review and Network Meta-analysis

BACKGROUND AND AIMS

Endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic biliary drainage, and endoscopic ultrasound (EUS)-guided biliary drainage are all established techniques for drainage of malignant biliary obstruction. This network meta-analysis (NMA) was aimed at comparing all 3 modalities to each other.

MATERIALS AND METHODS

Multiple databases were searched from inception to October 2019 to identify relevant studies. All the patients were eligible to receive any one of the 3 interventions. Data extraction and risk of bias assessment was performed using standardized tools. Outcomes of interest were technical success, clinical success, adverse events, and reintervention. Direct meta-analyses were performed using the random-effects model. NMA was conducted using a multivariate, consistency model with random-effects meta-regression. The GRADE approach was followed to rate the certainty of evidence.

RESULTS

The final analysis included 17 studies with 1566 patients. Direct meta-analysis suggested that EUS-guided biliary drainage had a lower reintervention rate than ERCP. NMA did not show statistically significant differences to favor any one intervention with certainty across all the outcomes. The overall certainty of evidence was found to be low to very low for all the outcomes.

CONCLUSIONS

The available evidence did not favor any intervention for drainage of malignant biliary obstruction across all the outcomes assessed. ERCP with or without EUS should be considered first to allow simultaneous tissue acquisition and biliary drainage.

Cost-effectiveness analysis of alternative strategies for palliation of distal biliary obstruction after a failed cannulation attempt

OBJECTIVES

Occasionally alternative techniques such as precut sphincterotomy or percutaneous transhepatic cholangiography (PTC) are required to achieve access to the common bile duct. Tradeoffs exist, however, with respect to their complications and costs. Some experts believe that precut sphincterotomy should not be performed at all. We aimed to compare the cost-effectivenesses of metallic biliary stent placement after an initial failed cannulation attempt at ERCP utilizing precut sphincterotomy and placement utilizing PTC for palliation of jaundice. A cost-effectiveness analysis was performed, as viewed from the societal perspective.

METHODS

A decision analysis model was designed comparing precut sphincterotomy and PTC approaches for placement of a metallic biliary stent for palliation of jaundice in a patient with inoperable malignant distal biliary obstruction in whom an initial attempt at ERCP cannulation had failed. Baseline probabilities, obtained from the published literature, were varied through plausible ranges using sensitivity analysis. Charges were based on Medicare professional plus facility fees or diagnosis-related group rates for out- and inpatients, respectively. The outcome measured was cost per year of life.

RESULTS

Sensitivity analysis showed that precut sphincterotomy with subsequent PTC, if necessary, was the most cost-effective strategy provided the precut complication rate was <51% ($9,033/yr), versus $14,741/yr for PTC.

CONCLUSIONS

Precut sphincterotomy followed by PTC (if necessary) is the most cost-effective strategy for palliative biliary stenting in the setting of malignant distal biliary obstruction after a failed ERCP attempt. The endoscopic approach is best practiced by experienced endoscopists who minimize precut complication rates.

Cost analysis of magnetic resonance cholangiography in the management of inoperable hilar biliary obstruction

OBJECTIVE

Palliation of patients with Klatskin tumors involving both hepatic ducts is usually performed with bilateral biliary stent placement. Magnetic resonance cholangiopancreatography (MRCP) offers the ability to visualize the hepatic ducts without injection of contrast, thereby reducing the patient's risk of developing postprocedure bacterial cholangitis. We used decision analysis techniques to quantitate the cost-effectiveness of MRCP before stent placement versus routine placement of bilateral biliary stents in the setting of inoperable malignant hilar obstruction. In addition to determining which strategy was most economical, we used sensitivity analysis to identify the critical factors defining relative costs.

METHODS

A decision analysis model was designed comparing MRCP with subsequent unilateral biliary stent placement and double biliary stent placement approaches for palliation of jaundice in a patient with inoperable malignant hilar obstruction, as viewed from the societal perspective. Baseline probabilities, obtained from the published literature, were varied through plausible ranges using sensitivity analysis. Charges were based on Medicare professional plus facility fees or diagnosis-related group rates for out- and inpatients, respectively.

RESULTS

MRCP with subsequent directed unilateral stent placement was the least costly approach ($3806) compared with bilateral stent placement ($4275), provided the bilateral biliary stent complication rate was >3%. Bilateral stent placement needed to confer a survival advantage of at least 7 days over unilateral stent placement to become the more cost-effective approach.

CONCLUSIONS

The use of MRCP to guide biliary stent placement in a patient with inoperable hilar obstruction reduces the overall cost of treatment. The uncertainty of any survival advantage that bilateral biliary stent placement confers over unilateral stent placement makes cost-effectiveness difficult to assess.

Malignant biliary disease: percutaneous interventions

Interventional radiologists have an important role in the management of patients with malignant biliary obstruction. This article describes the techniques for percutaneous biliary drainage, insertion of biliary endoprostheses, and the management of occluded biliary endoprostheses. Most procedures are performed by using fluoroscopic guidance alone. Ultrasound is also a useful modality for guiding biliary drainage, particularly drainage of the left biliary ducts. Patients should be treated by internal drainage if possible. Metallic endoprostheses can be inserted at the time of the initial biliary drainage procedure. Plastic tubes should be inserted a few days after biliary drainage because of their relatively large size compared with metallic stents. Occluded plastic stents should be replaced. Blocked metallic stents should be treated either by placement of additional overlapping metallic stents or by placement of plastic stents within the metallic stent lumen.

Polyurethane-covered Nitinol Strecker stents as primary palliative treatment of malignant biliary obstruction

PURPOSE

To evaluate the clinical efficacy of the polyurethane-covered Nitinol Strecker stent in the treatment of patients with malignant biliary obstruction.

METHODS

Twenty-three covered stents produced by us were placed in 18 patients with malignant biliary obstruction. Jaundice was caused by cholangiocarcinoma (n = 5), pancreatic cancer (n = 6), gallbladder cancer (n = 4), metastatic lymph nodes (n = 2), and tumor of the papilla (n = 1).

RESULTS

The mean patency period of the stents was 37.5 weeks (5-106 weeks). Recurrent obstructive jaundice occurred in two patients (11%). Adequate biliary drainage over 50 weeks or until death was achieved in 17 of 18 patients (94.4%). Late cholangitis was observed in two patients whose stents bridged the ampulla of Vater. Other late severe complications were not encountered.

CONCLUSION

Although more study is necessary, our results suggest the clinical efficacy of our covered Nitinol Strecker stent in the management of obstructive jaundice caused by malignant diseases.

Utilization pattern and efficacy of nonsurgical techniques to establish drainage for high biliary obstruction

PURPOSE

To review the frequency and success of percutaneous and endoscopic techniques in the relief of high biliary obstruction.

MATERIALS AND METHODS

A search of the radiologic achieves was performed identifying 70 patients with cholangiographic demonstration of high biliary obstruction defined as proximal to the distal third of the extrahepatic bile duct. Record review determined the frequency and success rates of percutaneous and endoscopic techniques in providing biliary decompression for obstructive jaundice.

RESULTS

Endoscopic retrograde cholangiopancreatography was performed in 35 of 70 patients, providing initial endoscopic biliary decompression (EBD) in six patients (two subsequently required percutaneous intervention). Percutaneous biliary drainage (PBD) was attempted in 60 of 70 patients, providing initial decompression in 55 patients. PBD provided decompression after failed endoscopic biliary drainage in 18 of 26 patients. Endoscopic drainage was never attempted after failed percutaneous drainage. Overall EBD success was 23% and overall PBD success was 95%. The complication rate attributed to EBD was 26%; that attributed to PBD was 25%. For those patients who underwent attempts at both EBD and PBD, the complication rate was 16%.

CONCLUSION

At an institution with well-developed gastrointestinal medical services and interventional radiologic services, PBD was more successful in providing initial biliary decompression than endoscopic techniques for high biliary obstruction.

Expandable metallic biliary stents

Eighteen expandable metallic biliary stents were inserted in patients with malignant (16 patients) or benign (two patients) biliary strictures. Four were the Gianturco-Rosch biliary Z-stents and the remaining 14 were the Wallstent. The stents were delivered through either the endoscopic transpapillary (10 patients), percutaneous transhepatic (five patients) or combined percutaneous-endoscopic (three patients) route. No failure in implantation was encountered. Bile drainage was successful in all patients. Stent occlusions were observed in four patients with hilar obstruction due to tumour overgrowth above the stents at 30-67 days (mean 47.75 days) after insertion. The occlusions were drained percutaneously (two patients) or endoscopically (two patients). Migration of stent did not occur. After a median follow-up period of 170.5 days (range 57-731 days), 11 patients were still alive and free of jaundice. The median patency period of the stents for common bile duct and hilar obstruction was 288.5 days (range 117-731 days) and 61.5 days (range 30-188 days), respectively. The overall median patency period was 165 days. It is concluded that expandable metallic biliary stent is a useful adjunct to the treatment of malignant biliary obstructions with a better result in distal obstruction.

Clinical experience in 126 patients with tissue-proved proximal cholangiocarcinoma

The diagnosis and treatment of 126 consecutive patients with tissue-proved cholangiocarcinoma which originates in or proximal to the common hepatic duct was reviewed. They are further divided into the hilar type and peripheral type tumours. The clinical presentations were commonly compatible with the hilar type tumour. However, the accurate pre-operative diagnosis of the peripheral type tumour was difficult because of the frequent association with hepatolithiasis (43.3%) and the high prevalence of hepatocellular carcinoma (HCC) in Taiwan; 25% of these patients underwent surgery for chronic cholangitis and 12.5% for HCC rather than cholangiocarcinoma. Among the 40 (31.7%) patients who had tumour resections, 24 were hilar type and 16 were peripheral type. There were no operative deaths and the mean survival time was 36.1 months (27.9 months for the hilar types, 52.2 months for the peripheral types). Sixty-three (50%) patients with hilar type tumours were only suitable for palliative procedures to relieve the jaundice. The 30-day mortality rate was 50 and 33.3% for the patients who received non-surgical and surgical drainages, but zero for the patients who had surgical bypasses. All the bypass patients experienced > 50% decrease of serum bilirubin, but this effect was obtained in less than half the patients receiving drainage procedures. Surgical resection significantly prolonged the survival (resection vs palliation vs no treatment = 36.1 vs 6.6 vs 3.6 months, P < 0.05), but no survival advantage was achieved in any of the palliative therapies. Five cases with tumour resection survived > 5 years. We conclude that surgical resection offers the best prognosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Bilateral internal biliary drainage of hilar cholangiocarcinoma with modified Gianturco Z stents inserted via a single percutaneous tract

PURPOSE

Modified Gianturco Z stents were used in five patients with hilar cholangiocarcinoma to permit bilobar hepatic drainage via a single percutaneous tract.

PATIENTS AND METHODS

After successful negotiation of strictures from the ipsilateral hepatic duct to the contralateral hepatic duct and the common bile duct, a modified endoprosthesis--made by connecting two double-body Z stents with two stainless steel wires in order to leave a space in between--was implanted in one stricture and a 'space' was located at the hepatic confluence. A second endoprosthesis, a two- to six-body Z stent, was introduced into the second stricture through the 'space' of the initial endoprosthesis and was implanted so that a part of the endoprosthesis should overlap the initial endoprosthesis.

RESULTS

Optimal positioning of the two endoprostheses was successful in all patients.

CONCLUSION

The technique seems simple, safe, and reliable in reconstructing the bilateral hepatic ductal systems via a single percutaneous approach in patients with hilar cholangiocarcinoma.

Percutaneously placed Wallstent endoprosthesis in patients with malignant distal biliary obstruction

Seventy-five patients with malignant distal biliary obstruction were treated by percutaneously placed self-expandable Wallstent endoprostheses for palliative drainage. The stent diameter was 1 cm and its length 3.5-10.5 cm. Early complications occurred in 16 patients (21 per cent); they were related to the endoprosthesis in five (7 per cent) and serious in six (8 per cent). The 30-day mortality rate was 15 per cent, with a 1 per cent procedure-related mortality rate. Sixty-five patients died 6-365 (median 87) days after stent insertion and four had recurrence of obstruction after 21-341 (median 152) days. Reobstruction was the result of tumour ingrowth in one patient, angling of the stent in one and an unestablished cause in two. Ten patients were alive without obstruction 31-383 (median 65) days after stent insertion. Percutaneous use of the Wallstent endoprosthesis allows easy insertion; reobstruction is rare.

Percutaneous metallic self-expandable endoprostheses in malignant hilar biliary obstruction

Forty-five patients with malignant hilar obstruction were treated with a total of 68 percutaneously inserted metallic self-expandable endoprostheses (Wallstents) for palliative biliary drainage. The stent diameter was 1 cm; the length was 3.5 to 10.5 cm. Early complications occurred in seven patients (16%), including cholangitis in four patients (9%). The 30-day mortality rate was 9%, with two procedure-related deaths (4%). Of the 45 patients, 29 died between 10 and 550 days (median, 126 days) after stent insertion. Reobstruction occurred in 13 of these patients after 26 to 184 days (median, 105 days). Sixteen patients were alive 44 to 737 days (median, 305 days) after stent insertion. Reobstruction occurred in four patients after 142 to 279 days (median, 246 days). The cause of reobstruction was proximal overgrowth in seven patients; distal overgrowth in four patients; and tumor ingrowth and proximal overgrowth, tumor ingrowth, hemobilia, and angling of the stent in one patient each. The cause of reobstruction was not established in two patients. Reintervention was performed in 14 patients (31%). Because reobstruction of Wallstent endoprostheses is primarily not stent-related but rather is caused by tumor progression, and because insertion and reintervention is easier, we consider the use of the Wallstent in malignant hilar biliary obstruction advantageous in comparison with plastic stents.

Peroral radiographic placement of biliary stents

The authors describe a modification of peroral-transhepatic placement of biliary stents for patients with malignant biliary obstruction. A stent is "pulled" into place perorally. The procedure can be performed with simple, readily available commercial materials. An endoscopist is not required. This method is cost-effective, less cumbersome, and easier to perform than the standard methods. In the authors' four cases, this modified approach appears equally effective.

Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma

A 20-year experience with 112 patients with cholangiocarcinoma was reviewed with reference to the demographic, etiologic, and clinical features and prognosis in the following two types: peripheral (originating from the intrahepatic small duct radicles) and hilar (originating from the major hepatic ducts at or near the junction of the right and left hepatic ducts). Seventy of the 112 patients were in the hilar group, and 42 were in the peripheral group. Prolonged high alcohol consumption was a prominent feature in both categories (45% and 37%, respectively). Among the women, 35% of those with the peripheral tumor had used oral contraceptive preparations. The major identifiable etiologic factor among the hilar tumors was ulcerative colitis, with or without sclerosing cholangitis, which was documented in 20 of 70 cases (28.6%), with an additional 4 patients having Crohn's disease. The hilar group mainly had obstructive jaundice initially, whereas abdominal pain and weight loss were the predominant symptoms in the peripheral type. Tumor recurrence was frequent in those undergoing resection or transplantation, and none of those undergoing chemotherapy or radiation therapy showed any objective evidence of response. Overall median survival time was poor in both groups at 12 months.

Percutaneous cholangioscopic or transpapillary insertion of self-expanding biliary metal stents

Fifty-two self-expanding metal stents were implanted in 39 patients with malignant (35 patients) or benign (4 patients) biliary stenoses. The stents were inserted and properly released by means of a 7 or 9 French gauge delivery catheter via the percutaneous (20 patients) or transpapillary (19 patients) route. In all cases the endoprostheses expanded to a diameter of 7 to 10 mm and achieved complete biliary tract drainage. Jaundice disappeared in 36 of the 39 patients. No early complication was observed. After a median follow-up of 121 days (range, 30 to 422 days), 19 of 36 patients are still alive and 17 died of non-procedure-related causes. Biliary re-obstruction occurred in five patients due to tumor overgrowth above or below the prosthesis (four patients) or bile encrustation (one patient). In patients with malignant stenoses, the probability of stent patency is 78% after 200 days. We conclude that large-bore metal stents are safe, effective, and provide better long-term patency than conventional endoprostheses.

Combined endoscopic and percutaneous stent insertion to overcome a problem of percutaneous stent insertion

Non-operative stent insertion is a well-accepted means of palliating malignant biliary obstruction. The endoscopic approach is often considered the procedure of choice, with the percutaneous technique reserved for endoscopy failures. We recently encountered a patient in whom both techniques proved unsuccessful initially, and in whom palliation was finally achieved by means of a combined endoscopic and percutaneous transhepatic procedure.